PARP – Inhibitor Combination Treatments Grant Program in United States

PARP – Inhibitor Combination Treatments Grant Program in United States

Section

Deadline Date
August 21, 2025
Donor Agency
Pfizer
Grant Size
$500,000 to $1 million

The Pfizer is accepting applications for PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape.

Funding Information
  • Individual projects requesting up to $350,000 will be considered. The estimated total available budget related to this RFP is $850,000. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. Multi-supported educational programs encouraged.
Target Audience
  • Community oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, genetic counselors, and other healthcare professionals involved in the care and treatment of patients with mCRPC.
Eligibility Criteria
  • Applicant organizations to this RFP must be based in the United States.
  • The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
  • Only organizations are eligible to receive grants, not individuals or physician-owned medical practices.
  • If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
  • For projects offering continuing education credit in the United States, the requesting organization must be accredited.

For more information, visit Pfizer.

Scroll to Top